$46.46
1.95% yesterday
Nasdaq, May 20, 09:48 pm CET
ISIN
US74366E1029
Symbol
PTGX

Protagonist Therapeutics, Inc. Stock price

$46.61
+0.81 1.77% 1M
+5.96 14.66% 6M
+8.01 20.75% YTD
+15.35 49.10% 1Y
+38.69 488.51% 3Y
+31.23 203.06% 5Y
+34.91 298.38% 10Y
Nasdaq, Closing price Tue, May 20 2025
+1.04 2.28%
ISIN
US74366E1029
Symbol
PTGX
Sector
Industry

Key metrics

Market capitalization $2.89b
Enterprise Value $2.33b
P/E (TTM) P/E ratio 61.27
EV/FCF (TTM) EV/FCF 6.94
EV/Sales (TTM) EV/Sales 11.19
P/S ratio (TTM) P/S ratio 13.90
P/B ratio (TTM) P/B ratio 4.19
Revenue growth (TTM) Revenue growth -34.02%
Revenue (TTM) Revenue $207.80m
EBIT (operating result TTM) EBIT $27.22m
Free Cash Flow (TTM) Free Cash Flow $335.29m
Cash position $574.36m
EPS (TTM) EPS $0.76
P/E forward negative
P/S forward 33.33
EV/Sales forward 26.83
Short interest 11.84%
Show more

Is Protagonist Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Protagonist Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Protagonist Therapeutics, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Protagonist Therapeutics, Inc. forecast:

Buy
91%
Hold
9%

Financial data from Protagonist Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
208 208
34% 34%
100%
- Direct Costs 2.38 2.38
28% 28%
1%
205 205
34% 34%
99%
- Selling and Administrative Expenses 36 36
7% 7%
17%
- Research and Development Expense 140 140
11% 11%
68%
30 30
81% 81%
14%
- Depreciation and Amortization 2.38 2.38
28% 28%
1%
EBIT (Operating Income) EBIT 27 27
82% 82%
13%
Net Profit 56 56
65% 65%
27%

In millions USD.

Don't miss a Thing! We will send you all news about Protagonist Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Protagonist Therapeutics, Inc. Stock News

Neutral
Accesswire
14 days ago
Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st Conference call to be held June 2nd at 8AM EDT to discuss rusfertide data presented at ASCO Full dataset from Phase 3 ICONIC-LEAD trial with icotrokinra in patients with moderate-to-severe plaque psoriasis (PsO) p...
Neutral
Accesswire
28 days ago
NEWARK, CA / ACCESS Newswire / April 23, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that an abstract was accepted for presentation at the Plenary Session at the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30 - June 3, 2025. Presentation Details: Presenting Author: Andrew T.
Neutral
Accesswire
about one month ago
NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced that on April 15, 2025 (the "Grant Date"), it issued an equity inducement award to a new employee upon his commencement of employment with the Company in...
More Protagonist Therapeutics, Inc. News

Company Profile

Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Head office United States
CEO Dinesh Patel
Employees 126
Founded 2006
Website www.protagonist-inc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today